ancitabine hydrochloride

We are ancitabine hydrochloride CAS:10212-25-6 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:ancitabine hydrochloride
CAS.NO:10212-25-6
Synonyms:2,2'-Anhydro-(1-β-D-arabinofuranosyl)cytosine Hydrochloride
2,2'-Anhydro-1-β-D-arabinofuranosylcytosine hydrochloride
2,2'-O-Cyclocytidine Hydrochloride
Ancitabine Hydrochloride
(-)-Cyclocytidine hydrochloride
Molecular Formula:C9H12ClN3O4
Molecular Weight:261.66200
 
Physical and Chemical Properties:
Density:2.01
Melting point:269-270ºC
Boiling point:442ºC
Flash point:221.1ºC
 
Specification:
Appearance:White or off-white crystalline powder
Assay(HPLC):≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Anti-tumor pharmaceutical intermediates, also used in the manufacture of eye drops.

ancitabine hydrochloride


Related News: Active pharmaceutical ingredients or APIs can be defined as the chemicals used to manufacture pharmaceutical drugs.3-Boronobenzoic acid Due to the cyclic nature of the upstream chemical products of the API, it is expected that the impact of price fluctuations of raw materials on the performance of API companies is unavoidable, but companies with thick product lines and the ability to produce intermediates are expected to minimize the upstream price impact.1155911-88-8 Due to the cyclic nature of the upstream chemical products of the API, it is expected that the impact of price fluctuations of raw materials on the performance of API companies is unavoidable, but companies with thick product lines and the ability to produce intermediates are expected to minimize the upstream price impact.402-49-3 Pharmaceutical intermediates: chemical raw materials or chemical products used in the process of pharmaceutical synthesis, are intermediate products in the process of producing APIs, and can be further processed into APIs.Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).

Related Products
Product Name
4-Fluorobenzotrifluoride View Details
(1S,3R,4S,5S)-4,6,6-trimethylbicyclo[3.1.1]heptane-3,4-diol View Details
5-chloro-3-methylpyridin-2-amine View Details
11-Phenyl-11,12-dihydroindolo[2,3-a]carbazole manufacturer 5-Chloro-2-nitrobenzaldehyde manufacturer 3-(Methylthio)-1-hexanol manufacturer dipicolinic acid manufacturer N-cyclohexyl-N-[2-(4-methyl-1-oxa-4-azoniacyclohex-4-yl)ethyl]methanediimine,4-methylbenzenesulfonic acid manufacturer